Abstract
The efficacy and tolerability of an oro-mucosal spray of a highly standardized cannabis-based medicine (CBM: Sativex®), was investigated in a randomized, double-blind, placebo-controlled, parallel-group trial of 66 MS patients with central pain. Each 100microlitre spray delivered 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg of cannabidiol (CBD). Sixty-four patients (96.9%) completed the randomized study (4 weeks), and 63 entered a long-term, open-label extension study (95.5%). Patients were allowed to self-titrate their medicine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
